All Oncology News

Harriet Kluger, MD, discussed the lack of clinical trial inclusion for patients with melanoma who have brain metastases, as well as promising regimens coming down the pike.

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.

Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center.

The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.

Researchers from the Hackensack Merdian Health John Theurer Cancer Center at Hackensack University Medical Center will present results from 46 cancer-related studies during the American Society of Hematology (ASH) 59th Annual Meeting, which will take place December 9

Adding ramucirumab to cisplatin and capecitabine or 5-FU in the frontline setting did not improve overall survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results from the phase III RAINFALL trial.

Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities

While the incidence of HPV-related oropharyngeal cancer is increasing, the risk for developing the disease remains low for most people.

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Hans Hammers, MD, PhD, discusses the game-changing combination of nivolumab and ipilimumab and highlighted other combinations that have potential in the treatment of patients with renal cell carcinoma.

The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.

The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.

Vincent K. Lam, MD, discusses the treatment paradigm for patients with ALK/ROS1-translocated NSCLC.

The combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) improved progression-free survival versus rituximab alone in patients with Waldenström macroglobulinemia.

Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.

The novel pan-TRK inhibitor larotrectinib (LOXO-101) achieved a 93% response rate in pediatric patients with TRK fusion–positive solid tumors.

Jerry W. Mitchell, MD, discusses the use of medical marijuana as a chronic pain relief for patients with hematologic malignancies ad other tumor types.

Olga Frankfurt, MD, discusses advances in the field of AML and challenges that lie ahead.

Proton beam therapy in children and young adults with nonhematologic malignancies of the head and neck appeared to be safe and delivered local control rates similar to those seen historically.

Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.

Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.

Brady L. Stein, MD, discusses the differences between the types of MPNs, the NCCN guideline changes, and the important role of JAK inhibitors.

George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.

Frank E. Mott, MD, discusses optimal treatment selection strategies for patients with NSCLC.

Melanie Majure, MD, discusses the optimal role chemotherapy for patients with TNBC and the importance of achieving a pCR.

The risk for graft-vs-host disease is low in children aged 2 to 12 years with acute leukemia, suggesting these patients may be good candidates for reduced preventative measures.

Sameh Mikhail, MD, discusses the promise of daratumumab, as well as the potential of medical marijuana to curb the adverse events seen with potent anticancer drugs.

The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.